Anthracycline Antibiotic Agent - Explore the Science & Experts | ideXlab


Scan Science and Technology

Contact Leading Edge Experts & Companies

Anthracycline Antibiotic Agent

The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform

Anthracycline Antibiotic Agent – Free Register to Access Experts & Abstracts

Yaoxian Xuan – One of the best experts on this subject based on the ideXlab platform.

  • Angelica sinensis: A Novel Adjunct to Prevent Doxorubicin‐Induced Chronic Cardiotoxicity
    Basic & clinical pharmacology & toxicology, 2007
    Co-Authors: Yanfei Xin, Guoliang Zhou, Min Shen, Yunxiang Chen, Shupeng Liu, Guo-chan Chen, Hao Chen, Zhenqiang You, Yaoxian Xuan

    Abstract:

    Doxorubicin is an Anthracycline Antibiotic Agent used in the treatment of a variety of solid and haematopoietic tumours, but its use is limited by formation of metabolites that induce acute and chronic cardiac toxicities. Angelica sinensis has been widely used to treat cardiovascular and cerebrovascular diseases in China. In the present study, we used an in vivo mouse model to explore whether A. sinensis could protect against doxorubicin-induced chronic cardiotoxicity. Male ICR mice were treated with distilled water or water extraction of A. sinensis (15 g/kg, orally) daily for 4 weeks, followed by saline or doxorubicin (15 mg/kg, intravenously) treatments weekly. Cardiotoxicity was assessed by electrocardiograph, antioxidant activity in cardiac tissues, serum levels of creatine kinase, aspartate aminotransferase (AST) and histopathological change in cardiac tissues. A cumulative dose of doxorubicin (60 mg/kg) caused animal death and myocardial injury characterized by increased QT interval and decreased heart rate in electrocardiograph, decrease of heart antioxidant activity, increase of serum AST, as well as myocardial lesions. Pre-treatment with A. sinensis significantly reduced mortality and improved heart performance of the doxorubicin-treated mice as evidenced from normalization of antioxidative activity and serum AST, preventing loss of myofibrils as well as improving arrhythmias and conduction abnormalities. Furthermore, the in vitro cytotoxic study showed that A. sinensis did not compromise the antitumour activity of doxorubicin. These results suggested that A. sinensis elicited a typical cardioprotective effect on doxorubicin-related oxidative stress, and could be a novel adjunct in the combination with doxorubicin chemotherapy.

    Free Register to Access Article

Wen Tan – One of the best experts on this subject based on the ideXlab platform.

  • Synthesis of Isosteviol analogues as potential protective Agents against Doxorubicin-induced cardiomyopathy in zebrafish embryos.
    Bioorganic & medicinal chemistry letters, 2019
    Co-Authors: R. Jayachandra, Haishan Zhao, Cheng Zuchun, Liping Luo, Tingwei Sun, Wen Tan

    Abstract:

    Abstract Doxorubicin (DOX) is a powerful Anthracycline Antibiotic Agent which is widely used to treat various types of cancers. Despite efficacy, it displays severe cardiotoxic side effects. Discovery of novel and effective protective Agents against DOX-induced cardiotoxicity has been a subject of great interest. Herein, we report the synthesis of two series of analogues of Isosteviol (ISV) 1 with modifications at C-16, C-19 positions as the first series and at C-15, C-16 positions as the other series. Interestingly second series analogues have shown a potential protective effect against DOX-induced cardiotoxicity in zebrafish embryos in vivo. Further, we have demonstrated that the synthesized new analogues of ISV, prevented the morphological distortions caused due to DOX cardiotoxicity in zebrafish heart and the associated cardiac impairments.

    Free Register to Access Article

Yanfei Xin – One of the best experts on this subject based on the ideXlab platform.

  • Angelica sinensis: A Novel Adjunct to Prevent Doxorubicin‐Induced Chronic Cardiotoxicity
    Basic & clinical pharmacology & toxicology, 2007
    Co-Authors: Yanfei Xin, Guoliang Zhou, Min Shen, Yunxiang Chen, Shupeng Liu, Guo-chan Chen, Hao Chen, Zhenqiang You, Yaoxian Xuan

    Abstract:

    Doxorubicin is an Anthracycline Antibiotic Agent used in the treatment of a variety of solid and haematopoietic tumours, but its use is limited by formation of metabolites that induce acute and chronic cardiac toxicities. Angelica sinensis has been widely used to treat cardiovascular and cerebrovascular diseases in China. In the present study, we used an in vivo mouse model to explore whether A. sinensis could protect against doxorubicin-induced chronic cardiotoxicity. Male ICR mice were treated with distilled water or water extraction of A. sinensis (15 g/kg, orally) daily for 4 weeks, followed by saline or doxorubicin (15 mg/kg, intravenously) treatments weekly. Cardiotoxicity was assessed by electrocardiograph, antioxidant activity in cardiac tissues, serum levels of creatine kinase, aspartate aminotransferase (AST) and histopathological change in cardiac tissues. A cumulative dose of doxorubicin (60 mg/kg) caused animal death and myocardial injury characterized by increased QT interval and decreased heart rate in electrocardiograph, decrease of heart antioxidant activity, increase of serum AST, as well as myocardial lesions. Pre-treatment with A. sinensis significantly reduced mortality and improved heart performance of the doxorubicin-treated mice as evidenced from normalization of antioxidative activity and serum AST, preventing loss of myofibrils as well as improving arrhythmias and conduction abnormalities. Furthermore, the in vitro cytotoxic study showed that A. sinensis did not compromise the antitumour activity of doxorubicin. These results suggested that A. sinensis elicited a typical cardioprotective effect on doxorubicin-related oxidative stress, and could be a novel adjunct in the combination with doxorubicin chemotherapy.

    Free Register to Access Article